This study aims to test the safety, efficacy and potential mechanism of action of the SinuSonic device on adults with upper respiratory infection (URI). SinuSonic is a medical device that utilizes sound and pressure combined with normal breathing. The study will have 2 aims. Aim 1 willdetermine if Sinusonic decreases the number of URIs experienced during an 8 week fall URI season. Subjects will use an active device (positive expiratory pressure and 128 Hz) or a sham device (no positive expiratory pressure and 1,000 Hz) for 1 min tid for 8 weeks. Aim 2 will determine if Sinusonic decreases the severity and duration of community acquired viral URIs. Subjects will use active or sham device as above.

Inclusion Criteria:

• Adults 18 years or older with no transient symptoms of any URI or allergies at baseline.

Exclusion Criteria:

• Any transient ENT condition that may impact upper airway to include acute sinusitis or otitis.
• Any upper respiratory illness within last 2 weeks
• TSS will be measured at baseline as described above and must be <9 for inclusion (Eccles etal).
• Topical decongestant use in last week
• Current nasal crusting or history of ulceration or perforation
• History of severe nose bleeding within last 3 months
• Known pregnancy
• Immunosuppressed condition or on immune modulating medications such as prednisone or chemotherapy
• Allergic sensitivity to silicone or any other component of device
• Inability to read and understand English
• Inability to perform treatment due to underlying medical condition

Not Applicable. The investigators plan to publish this study.

8 weeks